1515 Results
Sort By:
Published on October 2, 2019
Scientists at Arizona State University’s Biodesign Institute now report on the identification of more than 200,000 cancer neoantigens, which could feasibly lead to the development of broad-spectrum cancer vaccines, as well as tumor type-specific treatments or patient-personalized vaccines. “In a cancer cell, it turns out that all levels of information…
Published on September 26, 2019
Investigators at the Dana-Farber Cancer Institute, in conjunction with researchers at the Broad Institute of MIT and Harvard, have discovered that a metabolic imbalance in some cancer patients following treatment with a checkpoint inhibitor drug, nivolumab, is associated with resistance to the immunotherapy agent and shorter survival. Findings from the…
Published on September 16, 2019
Myriad Genetics said today it will assess the clinical utility of its Prolaris test in men diagnosed with prostate cancer, through a collaboration with the Leeds Centre for Personalised Medicine and Health (LCPMH) whose value was not disclosed. Myriad and LCPMH plan to partner on a study designed to evaluate the…
Published on September 10, 2019
A study published by Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), demonstrates that Personal Genome Diagnostics’ (PGDx) liquid biopsy technology can detect microsatellite instability (MSI) in circulating tumor DNA (ctDNA), and by doing so can estimate the likelihood of both an immediate and durable response…
Published on September 9, 2019
Thermo Fisher Scientific said today it will develop a companion diagnostic for Eli Lilly’s Phase I/II cancer candidate LOXO-292 (selpercatinib) through a collaboration whose value was not disclosed. The companion diagnostic will use Thermo Fisher’s next-generation sequencing-based Oncomine Dx Target Test to identify certain non-small cell lung cancer (NSCLC) and…
Published on September 5, 2019
Reaching more than $140 million in total to date, Repare Therapeutics completed an $82.5 Series B financing with the aim of pushing two of its synthetic lethality targeted therapeutics (RP-3500 and “Manchester”) into early clinical studies. Cowen Healthcare Investments led the financing and was joined by OrbiMed, Redmile, BVF Partners L.P.…
Published on August 29, 2019
The Leukemia & Lymphoma Society (LLS) said it has more than doubled its funding of research into childhood blood cancers, adding 20 new grants valued at more than $13.8 million to its 2019 portfolio. The new pediatric grants are part of the LLS Children’s Initiative: Cures and Care for Children,…
Published on August 27, 2019
Researchers at Institute for Systems Biology (ISB) have developed a method using using single-cell analysis to measure metabolic activities in rare disseminated tumor cells taken from non-small cell lung cancer (NSCLC) patients that can accurately predict how patients will respond to various cancer therapies, and how treatments will impact a…
Published on August 23, 2019
Researchers at Moffitt Cancer Center have partnered with investigators at the Dana-Farber Cancer Institute and Foundation Medicine to develop what Moffitt said was the largest descriptive genomic analysis to date of patients with Merkel cell carcinoma (MCC). MCC is a rare aggressive skin tumor that is diagnosed in approximately 2,000…
Published on August 9, 2019
Fecal transplants from long-term survivors of pancreatic cancer patients to newly diagnosed ones may one day save lives. That’s according to a new study published in the 8 August 2019 issue of Cell that found that a key difference between the few pancreatic cancer patients who survive long-term and the…
Published on August 5, 2019
Scientists headed by a team at the Institute of Cancer Research, London (ICR) have used artificial intelligence (AI) and machine learning (ML) to discover five new subtypes of breast cancer that could help clinicians deliver the most effective therapies—including immunotherapy—for individual patients, as well as potentially direct the development of…
Published on July 18, 2019
Researchers have discovered the mechanism by which a recently described subtype of aggressive prostate cancer spreads, even after treatment with next-generation androgen receptor (AR) inhibitors. They also report pre-clinical results in which they combine an inhibitor molecule with current immunotherapy drugs in mouse models to halt metastasis – even reversing…
Published on July 18, 2019
If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark (since acquired by Agilent Technologies) received authorization to market HercepTest. The immunohistochemistry (IHC) assay was designed to detect human epidermal growth factor receptor 2 (HER2) protein…
Published on July 2, 2019
It might be time for researchers to take another look at targeted cancer drugs that have ‘failed’ clinical trials in the past. That’s according to a new study that different cancer types respond differently to targeted therapies. The findings suggest that previous participants should not have been included in studies…
Published on July 1, 2019
One key to developing a treatment for Huntington’s disease (HD), according to many researchers, involves the challenging task of reducing the expression of the patient’s mutated copy of the huntingtin gene (HTT) while leaving the wild type copy untouched. A collaborative project between Sangamo Therapeutics and the CHDI foundation, a…